19714-74-0

Usage

Uses

Used in Pharmaceutical Industry:
Benzene, 1-chloro-3-cyclopropylis used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, Benzene, 1-chloro-3-cyclopropylis employed as a building block for the creation of pesticides and other agrochemicals, contributing to enhanced crop protection and yield.
Used in Dye Production:
Benzene, 1-chloro-3-cyclopropylis utilized in the production of dyes, particularly those requiring its specific chemical structure to achieve desired color properties and stability.
Used as a Solvent in Industrial Processes:
This chemical compound is also used as a solvent in various industrial processes, where its unique properties facilitate chemical reactions or help dissolve other substances.

Upstream product

• 19714-77-3 1,3-Dibrom-1-(m-chlor-phenyl)-propan 
• 1607-29-0 bis((1-methylcyclopropyl)formyl)peroxide 
• 108-90-7 chlorobenzene 
• 873-49-4 cyclopropylbenzene 
• 75-11-6 diiodomethane 
• 2039-85-2 3-Chlorostyrene 
• 58824-53-6 1-(3-chlorophenyl)prop-2-en-1-ol 
• 411235-57-9 cyclopropylboronic acid 
• 541-73-1 1,3-Dichlorobenzene 
• 108-37-2 1-bromo-3-chlorobenzene 
• 3002-94-6 cyclopropyllithium 
• 23719-80-4 cyclopropylmagnesium bromide 

Downstream Products

• 1049730-10-0 3-(cyclopropylphenyl)boronic acid 

Relevant academic research and scientific papers

Intermolecular Electrophilic Bromoesterification and Bromoetherification of Unactivated Cyclopropanes

1,3-difunctionalization of cyclopropane is an useful organic transformation. The corresponding 1,3-difunctionalized products are synthetic synthons and building blocks in many organic syntheses. Many existing ring-opening difunctionalization methodologies rely primarily on the use of donor?acceptor cyclopropanes, while the difunctionalization of unactivated cyclopropanes is less exploited. In this research, 1,3-bromoesterification and 1,3-bromoetherification of unactivated cyclopropanes were successfully achieved using N-bromosuccinimide as the brominating agent with high yields and regioselectivity. (Figure presented.).

Synthetic method of 3-cyclopropyl-benzeneboronic acid

The invention discloses a synthetic method of 3-cyclopropyl-benzeneboronic acid, and belongs to the technical field of organic synthesis. The synthetic method comprises the steps: 3-chlorobromobenzeneand cyclopropylboronic acid serve as starting raw mater

Murahashi Cross-Coupling at ?78 °C: A One-Pot Procedure for Sequential C?C/C?C, C?C/C?N, and C?C/C?S Cross-Coupling of Bromo-Chloro-Arenes

The coupling of organolithium reagents, including strongly hindered examples, at cryogenic temperatures (as low as ?78 °C) has been achieved with high-reactivity Pd-NHC catalysts. A temperature-dependent chemoselectivity trigger has been developed for the selective coupling of aryl bromides in the presence of chlorides. Building on this, a one-pot, sequential coupling strategy is presented for the rapid construction of advanced building blocks. Importantly, one-shot addition of alkyllithium compounds to Pd cross-coupling reactions has been achieved, eliminating the need for slow addition by syringe pump.

Lewis Base-Promoted Ring-Opening 1,3-Dioxygenation of Unactivated Cyclopropanes Using a Hypervalent Iodine Reagent

A facile and effective system has been developed for the regio- and chemoselective ring-opening/electrophilic functionalization of cyclopropanes through C?C bond activation by [bis(trifluoroacetoxy)iodo]benzene with the aid of the Lewis basic promoter p-toluenesulfonamide. The p-toluenesulfonamide-promoted system works well for a wide range of cyclopropanes, resulting in the formation of 1,3-diol products in good yields and regioselectivity.

NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

FREE RADICAL CHLORINATION AND ONE-ELECTRON OXIDATION OF ARYLCYCLOPROPANES. DESIGNER PROBES FOR CYTOCHROME P-450 HYDROXYLATION MECHANISMS

Arylcyclopropyl radicals can be formed under mild conditions (phase-transfer-catalyzed chlorination) and give rise to cyclopropyl products; in contrast one-electron oxidation of arylcyclopropanes by Mn(OAc)3 leads to fragmentation of the cyclopropane ring and the formation of acyclic products.